Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Application, By Region and Competition, 2020-2030F

Description

Global Hereditary Angioedema Therapeutics Market was valued at USD 4.36 Billion in 2024 and is expected to reach USD 7.28 Billion in the forecast period with a CAGR of 8.89% through 2030. The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate diagnosis, allowing for timely intervention and better disease management. Pharmaceutical companies are focusing on developing targeted therapies, including monoclonal antibodies and small-molecule inhibitors, to provide long-term prophylaxis and acute treatment solutions. The growing prevalence of hereditary angioedema, coupled with rising healthcare expenditure and patient advocacy efforts, is further supporting market growth. Furthermore, regulatory approvals for innovative therapies and the emergence of subcutaneous and oral treatment options are enhancing patient adherence and convenience, creating a favorable outlook for the industry.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.36 Billion
Market Size 2030	USD 7.28 Billion
CAGR 2025-2030	8.89%
Fastest Growing Segment	Prophylaxis
Largest Market	North America

A strong pipeline of novel drugs and increased investment in research and development are shaping the competitive landscape. Biopharmaceutical companies are exploring next-generation therapies that offer enhanced efficacy, fewer side effects, and improved administration methods. The shift from intravenous to subcutaneous and oral treatments is transforming the standard of care, reducing the burden on patients and healthcare providers. Collaborations and strategic partnerships between pharmaceutical firms, research institutions, and patient organizations are accelerating drug development and market penetration. The expansion of prophylactic treatments is expected to drive long-term market sustainability, as more patients seek preventive measures rather than relying solely on acute treatments.

Key Market Drivers

Advancements in Research and Development (R&D)

Advancements in Research and Development (R&D) have been pivotal in boosting the Global Hereditary Angioedema Therapeutics Market. Hereditary Angioedema is a rare genetic disorder characterized by debilitating and unpredictable swelling episodes that can be life-threatening. In recent years, the relentless pursuit of scientific knowledge and innovative therapies has transformed the landscape of HAE treatment.

One of the most significant drivers of market growth has been the breakthrough discoveries in understanding the underlying mechanisms of HAE. Researchers have delved deep into the genetic and biochemical aspects of the disease, leading to a more precise understanding of how it develops and progresses. This increased knowledge has paved the way for the development of targeted therapies that are specifically designed to address the root causes of HAE.

Monoclonal antibodies, in particular, have emerged as a revolutionary approach in HAE therapeutics. These monoclonal antibodies, such as lanadelumab and ecallantide, have been engineered to specifically inhibit the activity of proteins like plasma kallikrein, which play a critical role in HAE attacks. This precision in drug design has proven highly effective in preventing and managing HAE episodes, providing patients with newfound hope and relief from the burden of their condition.

Key Market Challenges

High Treatment Costs

The High treatment costs have emerged as a significant obstacle hindering the growth and accessibility of the Global Hereditary Angioedema Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. While advancements in therapeutics have improved the quality of life for HAE patients, the exorbitant cost of these treatments poses a considerable challenge. The prohibitively high cost of treatment makes these life-saving therapies inaccessible to a substantial portion of HAE patients, especially those without comprehensive health insurance coverage. This leads to disparities in access to care, with only a fraction of those in need benefiting from the latest advancements in HAE therapeutics.

For individuals who manage to access HAE therapies, the financial strain can be overwhelming. Copayments, deductibles, and out-of-pocket expenses can quickly accumulate, potentially forcing patients to make difficult choices between their healthcare needs and other essential expenses.

Access to HAE treatments is even more challenging in regions with limited healthcare resources and lower income levels. This exacerbates global healthcare disparities, where patients in wealthier nations have greater access to cutting-edge treatments, while those in less affluent regions struggle to secure even basic care.

Key Market Trends

Personalized Medicine Approaches

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the extremities, face, gastrointestinal tract, and airway. This condition is caused by mutations in the SERPING1 gene, leading to deficient or dysfunctional C1 inhibitor (C1-INH) proteins, which play a crucial role in regulating inflammatory pathways.

Personalized medicine has significantly advanced the management of HAE by tailoring treatments to individual genetic profiles and disease manifestations. The process begins with precise genetic testing to identify specific mutations in the SERPING1 gene, which helps determine the subtype of HAE a patient has. This accurate diagnosis is essential, as it guides the selection of targeted therapies that address the underlying pathophysiological mechanisms.

For instance, patients with Type I HAE, characterized by low levels of functional C1-INH, may benefit from C1-INH replacement therapies such as Berinert or Cinryze. These treatments work by supplementing the deficient protein, thereby preventing or reducing the frequency of swelling episodes. Conversely, patients with normal C1-INH levels but dysfunctional protein (Type II HAE) might respond better to therapies that inhibit the kallikrein-kinin pathway, such as lanadelumab (Takhzyro), a monoclonal antibody that targets plasma kallikrein to prevent bradykinin formation, a key mediator of swelling in HAE.

Key Market Players

Shire plc
Sanofi SA
Pharming Healthcare Inc.
Attune Pharmaceuticals
Adverum Biotechnologies
Arrowhead Pharmaceuticals
Ionis Pharmaceuticals
BioCryst Pharmaceuticals Inc.
CSL Behring.
CENTOGENE N.V

Report Scope:

In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hereditary Angioedema Therapeutics Market, By Drug Class:

C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Other Drug Classes

Hereditary Angioedema Therapeutics Market, By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Other Distribution Channels

Hereditary Angioedema Therapeutics Market, By Application:

Prophylaxis
On-demand

Hereditary Angioedema Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.

Available Customizations:

Global Hereditary Angioedema Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hereditary Angioedema Therapeutics Market Outlook

4.1. Market Size & Forecast
- 4.1.1. By Value
4.2. Market Share & Forecast
- 4.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
- 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
- 4.2.3. By Application (Prophylaxis, On-demand)
- 4.2.4. By Region
- 4.2.5. By Company (2024)
4.3. Market Map
- 4.3.1. By Drug Class
- 4.3.2. By Distribution Channel
- 4.3.3. By Application
- 4.3.4. By Region

5. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class
- 5.2.2. By Distribution Channel
- 5.2.3. By Application
- 5.2.4. By Country
5.3. Asia Pacific: Country Analysis
- 5.3.1. China Hereditary Angioedema Therapeutics Market Outlook
  - 5.3.1.1. Market Size & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share & Forecast
    - 5.3.1.2.1. By Drug Class
    - 5.3.1.2.2. By Distribution Channel
    - 5.3.1.2.3. By Application
- 5.3.2. India Hereditary Angioedema Therapeutics Market Outlook
  - 5.3.2.1. Market Size & Forecast
    - 5.3.2.1.1. By Value
  - 5.3.2.2. Market Share & Forecast
    - 5.3.2.2.1. By Drug Class
    - 5.3.2.2.2. By Distribution Channel
    - 5.3.2.2.3. By Application
- 5.3.3. Australia Hereditary Angioedema Therapeutics Market Outlook
  - 5.3.3.1. Market Size & Forecast
    - 5.3.3.1.1. By Value
  - 5.3.3.2. Market Share & Forecast
    - 5.3.3.2.1. By Drug Class
    - 5.3.3.2.2. By Distribution Channel
    - 5.3.3.2.3. By Application
- 5.3.4. Japan Hereditary Angioedema Therapeutics Market Outlook
  - 5.3.4.1. Market Size & Forecast
    - 5.3.4.1.1. By Value
  - 5.3.4.2. Market Share & Forecast
    - 5.3.4.2.1. By Drug Class
    - 5.3.4.2.2. By Distribution Channel
    - 5.3.4.2.3. By Application
- 5.3.5. South Korea Hereditary Angioedema Therapeutics Market Outlook
  - 5.3.5.1. Market Size & Forecast
    - 5.3.5.1.1. By Value
  - 5.3.5.2. Market Share & Forecast
    - 5.3.5.2.1. By Drug Class
    - 5.3.5.2.2. By Distribution Channel
    - 5.3.5.2.3. By Application

6. Europe Hereditary Angioedema Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Distribution Channel
- 6.2.3. By Application
- 6.2.4. By Country
6.3. Europe: Country Analysis
- 6.3.1. France Hereditary Angioedema Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Distribution Channel
    - 6.3.1.2.3. By Application
- 6.3.2. Germany Hereditary Angioedema Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Distribution Channel
    - 6.3.2.2.3. By Application
- 6.3.3. Spain Hereditary Angioedema Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Distribution Channel
    - 6.3.3.2.3. By Application
- 6.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Drug Class
    - 6.3.4.2.2. By Distribution Channel
    - 6.3.4.2.3. By Application
- 6.3.5. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Drug Class
    - 6.3.5.2.2. By Distribution Channel
    - 6.3.5.2.3. By Application

7. North America Hereditary Angioedema Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Distribution Channel
- 7.2.3. By Application
- 7.2.4. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Distribution Channel
    - 7.3.1.2.3. By Application
- 7.3.2. Mexico Hereditary Angioedema Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Distribution Channel
    - 7.3.2.2.3. By Application
- 7.3.3. Canada Hereditary Angioedema Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Distribution Channel
    - 7.3.3.2.3. By Application

8. South America Hereditary Angioedema Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Distribution Channel
- 8.2.3. By Application
- 8.2.4. By Country
8.3. South America: Country Analysis
- 8.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Distribution Channel
    - 8.3.1.2.3. By Application
- 8.3.2. Argentina Hereditary Angioedema Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Distribution Channel
    - 8.3.2.2.3. By Application
- 8.3.3. Colombia Hereditary Angioedema Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Distribution Channel
    - 8.3.3.2.3. By Application

9. Middle East and Africa Hereditary Angioedema Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Distribution Channel
- 9.2.3. By Application
- 9.2.4. By Country
9.3. MEA: Country Analysis
- 9.3.1. South Africa Hereditary Angioedema Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Distribution Channel
    - 9.3.1.2.3. By Application
- 9.3.2. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Distribution Channel
    - 9.3.2.2.3. By Application
- 9.3.3. UAE Hereditary Angioedema Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Distribution Channel
    - 9.3.3.2.3. By Application

10. Market Dynamics

10.1. Drivers
10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions

12. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. Shire plc
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Current Capacity Analysis
- 14.1.5. Financials (In case of listed)
- 14.1.6. Recent Developments
- 14.1.7. SWOT Analysis
14.2. Sanofi SA
14.3. Pharming Healthcare Inc.
14.4. Attune Pharmaceuticals
14.5. Adverum Biotechnologies
14.6. Arrowhead Pharmaceuticals
14.7. Ionis Pharmaceuticals
14.8. BioCryst Pharmaceuticals Inc.
14.9. CSL Behring.
14.10. CENTOGENE N.V.